ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.

Zhejiang Huahai Pharmaceutical Co., Ltd.

600521

CNE000001DL5

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
17.34 ^CNY	+0.35%		-0.91%	+18.20%

05-13	Huahai Pharmaceutical's Unit Gets Nod to Register Atomoxetine Hydrochloride Oral Solution	MT
05-02	Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21%	MT

Zhejiang Huahai Pharmaceutical Co. Ltd Appoints Luo Jialiang as Deputy General Manager

August 14, 2012

Zhejiang Huahai Pharmaceutical Co. Ltd. announced that its ninth session of fourth Directorate meeting held on August 14, 2012 approved the proposal of appointing Luo Jialiang as Deputy General Manager of the company.

Latest news about Zhejiang Huahai Pharmaceutical Co., Ltd.

Huahai Pharmaceutical's Unit Gets Nod to Register Atomoxetine Hydrochloride Oral Solution	05-13	MT
Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21%	05-02	MT
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Huahai Pharmaceutical Gets Approval to Market Busulfan Injection	04-23	MT
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.	04-18	CI
Zhejiang Huahai Pharmaceutical Gets Chinese Registration Nod for Torsemide Tablets	04-17	MT
Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 14, 2023 has closed with 7,023,600 shares, representing 0.48% for CNY 99.99 million.	04-16	CI
Zhejiang Huahai Pharmaceutical Forecasts Up to 65% Rise in Q1 Profit	04-16	MT
Shyndec Pharmaceutical's Unit Gets Nod to Register Empagliflozin Tablets	04-16	MT
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-15	CI
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.	04-01	CI
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.	01-02	CI
Zhejiang Huahai Pharmaceutical Gets US FDA's Nod for Pemetrexed Disodium for Injection	12-18	MT
Correction: Huahai Pharmaceutical Gets Nod to Amend Specifications for Irbesartan Tablets	12-11	MT
Huahai Pharmaceutical Gets Nod to Amend Spefication for Irbesartan Tablets	12-11	MT
Zhejiang Huahai Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	11-13	CI
Huahai Pharma Selling 1.4 Billion Yuan Shares For Capacity Expansion	11-10	MT
Huahai Pharma to Repurchase Up to 100 Million Yuan Shares	11-06	MT
Huahai Pharma Unit Gets FDA Nod to Trial Cancer Drug	11-06	MT
Zhejiang Huahai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	11-05	CI
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Huahai Pharma Registers Drug for Prostate Treatment	23-10-19	MT
Ningbo Menovo Pharma Registers Blood Pressure Drug	23-09-06	MT
Huahai Pharmaceutical Gets US FDA's Nod for Dicyclomine Hydrochloride Capsules	23-09-04	MT
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI

Chart Zhejiang Huahai Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Huahai Pharmaceutical Co., Ltd.

More charts

Company Profile

ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The Company also provides related technical support services. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Huahai Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

17.34 CNY

Average target price

18.5 CNY

Spread / Average Target

+6.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.	+18.20%	3.51B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B

Other Pharmaceuticals